NASDAQ:CDNA

CareDx Stock Forecast, Price & News

$77.18
+2.48 (+3.32 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$74.80
Now: $77.18
$77.71
50-Day Range
$57.62
MA: $69.90
$87.34
52-Week Range
$21.40
Now: $77.18
$99.83
Volume356,674 shs
Average Volume780,442 shs
Market Capitalization$4.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.84
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
CareDx logo

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDNA
CUSIPN/A
Phone415-287-2300
Employees456
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$127.07 million
Book Value$2.33 per share

Profitability

Net Income$-21,970,000.00

Miscellaneous

Market Cap$4.00 billion
Next Earnings Date4/29/2021 (Estimated)
OptionableOptionable

Headlines

CareDx (NASDAQ:CDNA) Shares Gap Down to $73.71
April 6, 2021 |  americanbankingnews.com
CareDx Enhances Leadership Team with Key Appointments
March 31, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

0.97 out of 5 stars

Medical Sector

1100th out of 2,021 stocks

Medical Laboratories Industry

20th out of 39 stocks

Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$77.18
+2.48 (+3.32 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CareDx (NASDAQ:CDNA) Frequently Asked Questions

Is CareDx a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CareDx stock.
View analyst ratings for CareDx
or view top-rated stocks.

What stocks does MarketBeat like better than CareDx?

Wall Street analysts have given CareDx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CareDx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is CareDx's next earnings date?

CareDx is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for CareDx
.

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) released its quarterly earnings results on Tuesday, February, 23rd. The company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.20. The firm had revenue of $58.64 million for the quarter, compared to analysts' expectations of $58.51 million. CareDx had a negative trailing twelve-month return on equity of 10.95% and a negative net margin of 11.79%.
View CareDx's earnings history
.

How has CareDx's stock been impacted by COVID-19 (Coronavirus)?

CareDx's stock was trading at $18.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CDNA shares have increased by 307.5% and is now trading at $77.18.
View which stocks have been most impacted by COVID-19
.

What guidance has CareDx issued on next quarter's earnings?

CareDx issued an update on its FY 2021 After-Hours earnings guidance on Wednesday, February, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $255-265 million, compared to the consensus revenue estimate of $249.81 million.

What price target have analysts set for CDNA?

6 Wall Street analysts have issued 1-year price targets for CareDx's stock. Their forecasts range from $35.00 to $98.00. On average, they anticipate CareDx's stock price to reach $75.83 in the next twelve months. This suggests that the stock has a possible downside of 1.7%.
View analysts' price targets for CareDx
or view top-rated stocks among Wall Street analysts.

Who are CareDx's key executives?

CareDx's management team includes the following people:
  • Dr. Peter Maag, Exec. Chairman (Age 54, Pay $1.08M)
  • Dr. Reginald Seeto, Pres, CEO & Director (Age 49, Pay $826k)
  • Ms. Sasha King M.B.A., Chief Marketing Officer (Age 35, Pay $509.2k)
  • Mr. Ankur Dhingra, Chief Financial Officer (Age 45)
  • Mr. Paul Ciccolella, Sr. VP of Global Operations
  • Mr. Amitabh Shukla, Sr. VP of Technology
  • Dr. Sham Dholakia DPHIL, M.D., Sr. VP of Medical Affairs & Clinical Operations
  • Mr. Kashif Rathore, Sr. VP of Digital Bus.
  • Mr. Alexander L. Johnson, Sr. VP of Products, Cell Therapy & Bus. Devel.
  • Dr. Robert N. Woodward Ph.D., Sr. VP of R&D

Who are some of CareDx's key competitors?

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Square (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

Who are CareDx's major shareholders?

CareDx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.19%), Calamos Advisors LLC (0.09%), Juncture Wealth Strategies LLC (0.03%), Mesirow Financial Investment Management Inc. (0.01%), Contravisory Investment Management Inc. (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Michael Goldberg, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King and William A Hagstrom.
View institutional ownership trends for CareDx
.

Which institutional investors are selling CareDx stock?

CDNA stock was sold by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc., Juncture Wealth Strategies LLC, Pacer Advisors Inc., Calamos Advisors LLC, and Contravisory Investment Management Inc.. Company insiders that have sold CareDx company stock in the last year include Michael Brian Bell, Michael Goldberg, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, and William A Hagstrom.
View insider buying and selling activity for CareDx
or view top insider-selling stocks.

Which institutional investors are buying CareDx stock?

CDNA stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc..
View insider buying and selling activity for CareDx
or or view top insider-buying stocks.

How do I buy shares of CareDx?

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $77.18.

How much money does CareDx make?

CareDx has a market capitalization of $4.00 billion and generates $127.07 million in revenue each year. The company earns $-21,970,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does CareDx have?

CareDx employs 456 workers across the globe.

What is CareDx's official website?

The official website for CareDx is www.caredxinc.com.

Where are CareDx's headquarters?

CareDx is headquartered at 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080.

How can I contact CareDx?

CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-287-2300 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.